Merck Expands Biosafety Testing Laboratory in Singapore

Merck, a leading science and technology company, is expanding its Singapore laboratory to provide advanced biosafety testing services for customers across the Asia Pacific region. The expansion builds on Merck's global testing expertise of over 75 years and marks a significant milestone in providing local contract testing services for the region's growing biopharma industry.

The Singapore BioReliance lab was opened in 2018, and the expansion will bring the total lab area to over 1,000 square meters. This facility will offer both Cell Line Characterisation services and GMP next-generation sequencing (NGS) capabilities, as well as advanced molecular methods including Blazar, a proprietary platform for rapid virus detection.

The expanded laboratory aims to support the industry's move towards state-of-the-art quality control testing of biologics and 3Rs (Replacement, Reduction, and Refinement of animal use) through advanced molecular methods. The expansion is also part of Merck's broader strategy to support the region's dynamic life science ecosystem and drive scientific progress.